Induction of Prolonged Mania During Ketamine Therapy for Reflex Sympathetic Dystrophy

Ricke, Amy K.; Snook, Riley; Anand, Amit

doi:10.1016/j.biopsych.2011.02.030

Cited by 33 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 An isolated case of mania following ketamine treatment has also been reported. 37 Clearly, substantially more data on longer-term safety and efficacy of ketamine in these populations are required.…”

Section: Discussionmentioning

confidence: 99%

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

Wan

Levitch²,

Perez³

et al. 2014

J. Clin. Psychiatry

193

154

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

Wan

Levitch²,

Perez³

et al. 2014

J. Clin. Psychiatry

193

154

View full text Add to dashboard Cite

show abstract

“…This has not been a problem in the larger trials to date (34, 51) or in two cases of extended treatment with ketamine (52). One case of mania attributed to ketamine infusion has been reported, however attributions of causality related to switches in mood state in bipolar disorder are extremely complicated and so this important issue awaits further rigorous study (53). …”

Section: Nmda Receptor Antagonists As Rapid-acting Antidepressantsmentioning

confidence: 99%

Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond

Krystal

Sanacora

Duman

2013

Biological Psychiatry

357

241

View full text Add to dashboard Cite

Traditional antidepressants require many weeks to reveal their therapeutic effects. However, the widely replicated observation that a single subanesthetic dose of the NMDA glutamate receptor antagonist, ketamine, produced meaningful clinical improvement within hours suggested that rapidly acting antidepressants might be possible. The ketamine studies stimulated a new generation of basic antidepressant research that identified new neural signaling mechanisms in antidepressant response and provided a conceptual framework linking a group of novel antidepressant mechanisms. This article presents the path that led to the testing of ketamine, considers its promise as an antidepressant, and reviews novel treatment mechanisms that are emerging from this line of research.

show abstract

“…Based on studies suggesting a glutamatergic hypofunction in BD (Dickerson et al, 2012; Rao et al, 2012b) and a case report of mania induction following ketamine therapy (Ricke et al, 2011), a study has proposed an animal model of mania induced by the rapid acting selective NMDA antagonist ketamine (Ghedim et al, 2012). During this paradigm, both lithium and VAP were able to partially prevent and reverse ketamine-induced hyperlocomotion with a significant reduction in OS measures in discrete brain areas involved in the pathophysiology of BD (Ghedim et al, 2012).…”

Section: Modelling Mania In Animals: Pharmacological Environmentamentioning

confidence: 99%

Modeling mania in preclinical settings: A comprehensive review

Sharma

Fries

Gálvez

et al. 2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

The current pathophysiological understanding of mechanisms leading to onset and progression of bipolar manic episodes remains limited. At the same time, available animal models for mania have limited face, construct, and predictive validities. Additionally, these models fail to encompass recent pathophysiological frameworks of bipolar disorder (BD), e.g. neuroprogression. Therefore, there is a need to search for novel preclinical models for mania that could comprehensively address these limitations. Herein we review the history, validity, and caveats of currently available animal models for mania. We also review new genetic models for mania, namely knockout mice for genes involved in neurotransmission, synapse formation, and intracellular signaling pathways. Furthermore, we review recent trends in preclinical models for mania that may aid in the comprehension of mechanisms underlying the neuroprogressive and recurring nature of BD. In conclusion, the validity of animal models for mania remains limited. Nevertheless, novel (e.g. genetic) animal models as well as adaptation of existing paradigms hold promise.

show abstract

Induction of Prolonged Mania During Ketamine Therapy for Reflex Sympathetic Dystrophy

Cited by 33 publications

References 8 publications

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond

Modeling mania in preclinical settings: A comprehensive review

Contact Info

Product

Resources

About